Navigating Treatment Selection for CLL in the Relapsed/Refractory Setting

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Administering precision-selected donor regulatory T-cell therapy significantly improves GVHD-free, relapse-free survival in patients undergoing allogeneic HCT.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

EHA 2025: Top 5 Takeaways for Hematologic Malignancy Management

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.

Preparing for Oncology Board Certification, Career Transitions, and Combating Burnout

Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.

ONCOLOGY Staff

Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease

Read about various aspects of career trajectories in oncology from the perspective of established clinicians, new attendings, and those waiting to sit for their medical board exams.

Related Content

American Society for Transplantation and Cellular Therapy

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Administering precision-selected donor regulatory T-cell therapy significantly improves GVHD-free, relapse-free survival in patients undergoing allogeneic HCT.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

EHA 2025: Top 5 Takeaways for Hematologic Malignancy Management

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Preparing for Oncology Board Certification, Career Transitions, and Combating Burnout

Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.

ONCOLOGY Staff